2-溴吡啶-4-甲酰胺 | 29840-73-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴吡啶-4-甲酰胺
• 中文别名: 2-溴吡啶-4-氨甲酰；2-溴异烟酰胺；2-溴异酰胺
• 英文名称: 2-bromopyridine-4-carboxamide
• 英文别名: 2-bromoisonicotinamide；2-bromo-4-pyridinecarboxamide；2-bromo-isonicotinamide；2-Brom-isonicotinsaeureamid
• CAS: 29840-73-1
• 化学式: C₆H₅BrN₂O
• 分子量: 201.023
• InChiKey: KCELTDZFDHPTBI-UHFFFAOYSA-N

物化性质

• 熔点：
  192°C
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解，未有已知危险反应。避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险标志：
  GHS07
• 危险性描述：
  H302,H319
• 危险性防范说明：
  P305 + P351 + P338
• 储存条件：
  密封保存，并置于冷藏环境中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromoisonicotinamide
Synonyms: 2-Bromo-4-pyridinecarboxamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromoisonicotinamide
CAS number: 29840-73-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H5BrN2O
Molecular weight: 201.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴吡啶-4-甲酰胺 在 劳森试剂 、 bis-triphenylphosphine-palladium(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 生成 乙硫异烟胺
  参考文献：
  名称：

  乙硫酰胺周围的有效模拟，以探索由结核分枝杆菌中的加强剂触发的硫酰胺类生物激活途径

  摘要：

  乙硫磷酰胺是治疗肺结核的二线化疗方案的关键抗生素前药。由于拜耳－维利格单加氧酶EthA在称为EthR的转录阻遏物的控制下进行了分枝杆菌生物激活作用，因此它靶向分枝菌酸的生物合成。最近，类似药物的分子SMARt-420触发了一种新的转录调节剂，称为EthR2，它可以使乙乙酰胺的隐蔽性生物激活途径失活。为了研究通过两种生物激活途径对一组硫代异烟酰胺的生物激活，我们开发了一种新的两步化学途径，可有效合成十八种乙硫酰胺类似物。这些衍生物的抗分枝杆菌活性的测定，通过相同的机制，这意味着类似代谢物的形成。另外，对脂族硫代异烟酰胺酰胺类似物进行了电化学研究，以观察其氧化电位是否与在两种增强剂存在或不存在下测得的抗结核活性相关。

  DOI：

  10.1016/j.ejmech.2018.09.038
• 作为产物：
  描述：

  2-羟基异烟酸 在 ammonium hydroxide 、 硫酸 、 三溴氧磷 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-溴吡啶-4-甲酰胺
  参考文献：
  名称：

  一种2-溴异烟腈的制备方法

  摘要：

  本发明公开了一种2‑溴异烟腈的制备方法，特点是包括以下步骤：1)将2‑羟基异烟酸和溴化试剂反应完全得到2‑溴异烟酸，2‑羟基异烟酸与溴化试剂的物质的量比为1：(2～5)；2)将2‑溴异烟酸酯和氨溶液反应得到2‑溴异烟酰胺，2‑溴异烟酸与氯化试剂的物质的量比为1：(1～5)；3)将2‑溴异烟酰胺和脱水试剂反应得到2‑溴异烟腈，2‑溴异烟酰胺与脱水试剂的物质的量比为1：(0.5‑4)，优点是工艺简单，反应条件温和，对环境友好，收率高，适合规模化生产。

  公开号：

  CN115724793A

文献信息

• [EN] NOVEL SUBSTITUTED SPIRO-[INDOLINE HETEROCYCLOALKANE] COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS SPIRO-[INDOLINE HETEROCYCLOALKANE] SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE
  申请人：GRUENENTHAL GMBH

  公开号：WO2017108204A1

  公开（公告）日：2017-06-29

  The invention relates to novel spiro-[indoline heterocycloalkane] compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

  这项发明涉及新型螺[吲哚杂环烷]化合物，其特征在于该化合物具有通式(I)，其中化学基团、取代基、变量和指数如描述中所定义，并且用作药物，特别是用作治疗可以通过抑制PDE4酶来治疗的疾病和病症的药物。
• Isonicotin- and nicotinamide derivatives of benzothiazoles
  申请人：——

  公开号：US20030134854A1

  公开（公告）日：2003-07-17

  The present invention relates to compounds of the formula 1 wherein R1, A and R are as described within. The compounds of the present invention have been found to be adenosine receptor ligands. Specifically, the compounds of the present invention have an affinity to the A 2A -receptor and are therefore useful in the treatment of diseases related to this receptor.

  本发明涉及具有以下公式的化合物1，其中R1、A和R如内部所述。本发明的化合物已被发现是腺苷受体配体。特别是，本发明的化合物对A2A受体具有亲和力，因此在治疗与该受体相关的疾病中非常有用。
• [EN] ANTIFUNGAL AGENTS<br/>[FR] AGENTS ANTIFONGIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2010019204A1

  公开（公告）日：2010-02-18

  Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs,,as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

  本文披露了恩富马富金的新颖衍生物，以及它们的药用盐、水合物和前药。还披露了包含这些化合物的组合物、制备这些化合物的方法以及将这些化合物用作抗真菌剂和/或（1,3）-β-D-葡聚糖合酶抑制剂的方法。所披露的化合物、它们的药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，可用于治疗和/或预防真菌感染及相关疾病和症状。
• High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide <i>N</i>-Methyltransferase (NNMT)
  作者：Rocco L. Policarpo、Ludovic Decultot、Elizabeth May、Petr Kuzmič、Samuel Carlson、Danny Huang、Vincent Chu、Brandon A. Wright、Saravanakumar Dhakshinamoorthy、Aimo Kannt、Shilpa Rani、Sreekanth Dittakavi、Joseph D. Panarese、Rachelle Gaudet、Matthew D. Shair

  DOI：10.1021/acs.jmedchem.9b01238

  日期：2019.11.14

  structure-based rational design led to the development of potent and selective alkynyl bisubstrate inhibitors of NNMT. The reported nicotinamide–SAM conjugate (named NS1) features an alkyne as a key design element that closely mimics the linear, 180° transition state geometry found in the NNMT-catalyzed SAM → NAM methyl transfer reaction. NS1 was synthesized in 14 steps and found to be a high-affinity, subnanomolar

  烟酰胺N-甲基转移酶（NNMT）是一种使用辅因子S使烟酰胺（NAM）甲基化的代谢酶-腺苷甲硫氨酸（SAM）。NNMT过表达与糖尿病，肥胖症和各种癌症有关。在这项工作中，基于结构的合理设计导致了NNMT的有效和选择性炔基双底物抑制剂的发展。报道的烟酰胺-SAM共轭物（命名为NS1）以炔烃为主要设计元素，其紧密模拟NNMT催化的SAM→NAM甲基转移反应中发现的线性180°过渡态几何形状。NS1分14步合成，是一种高亲和力的亚纳摩尔级NNMT抑制剂。X射线共晶结构和SAR研究表明，炔基连接子具有跨过NNMT的甲基转移通道的能力，具有理想的形状互补性。这项工作中报道的化合物代表了迄今为止报道的最有效和选择性的NNMT抑制剂。
• [EN] AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS AZAINDAZOLE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010036632A1

  公开（公告）日：2010-04-01

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

  公开的是化合物的公式（I），用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫性疾病，如风湿性关节炎和多发性硬化症。还公开了制备方法和使用方法。